Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation

Takashi Tagami; Hideo Yasunaga; Hiroyuki Yokota

doi:10.1186/s13054-017-1639-8

Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation

Crit Care. 2017 Mar 21;21(1):59. doi: 10.1186/s13054-017-1639-8.

Authors

Takashi Tagami^{1

2}, Hideo Yasunaga³, Hiroyuki Yokota⁴

Affiliations

¹ Department of Emergency and Critical Care Medicine, Nippon Medical School, Tama Nagayama Hospital, 2068512, Tama-shi, Tokyo, Japan. t-tagami@nms.ac.jp.
² Department of Clinical Epidemiology and Health Economics, The University of Tokyo, School of Public Health, Graduate School of Medicine, 1138555, Bunkyo-ku, Tokyo, Japan. t-tagami@nms.ac.jp.
³ Department of Clinical Epidemiology and Health Economics, The University of Tokyo, School of Public Health, Graduate School of Medicine, 1138555, Bunkyo-ku, Tokyo, Japan.
⁴ Department of Emergency and Critical Care Medicine, Nippon Medical School, 1138603, Bunkyo-ku, Tokyo, Japan.

Abstract

This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency medicine 2017. Other selected articles can be found online at http://ccforum.com/series/annualupdate2017 . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from http://www.springer.com/series/8901 .

Publication types

Review

MeSH terms

Amiodarone / pharmacology
Amiodarone / therapeutic use
Anti-Arrhythmia Agents / pharmacology*
Anti-Arrhythmia Agents / therapeutic use
Emergency Medical Services / methods
Humans
Intensive Care Units / organization & administration
Lidocaine / pharmacology
Lidocaine / therapeutic use
Out-of-Hospital Cardiac Arrest / drug therapy*
Placebos / pharmacology
Placebos / therapeutic use
Pyrimidinones / pharmacology
Pyrimidinones / therapeutic use
Ventricular Fibrillation / drug therapy*

Substances

Anti-Arrhythmia Agents
Placebos
Pyrimidinones
nifekalant
Lidocaine
Amiodarone